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ABSTRACT: Lantipeptides are ribosomally synthesized
and posttranslationally modiﬁed peptides containing
thioether cross-links. We describe the preparation of seven
diﬀerent lantipeptides in Escherichia coli and demonstrate
that this methodology can be used to incorporate nonpro-
teinogenic amino acids.
L
antipeptides are polycyclic peptides with thioether cross-
links formed by dehydration of Ser/Thr residues and sub-
sequent Michael additions of Cys residues to the resulting
dehydro amino acids as exempliﬁed in Figure 1 for nisin A.
These cross-links are introduced by posttranslational modiﬁca-
tion of a precursor peptide (generically termed LanA) and are
calledlanthionine(fromSer)ormethyllanthionine (fromThr);
1
lantipeptides with antimicrobial activities are called lantibiotics.
2
The posttranslational modiﬁcations take place only in the
C-terminal core peptide, but they require an N-terminal leader
peptidethatmustberemovedbyproteolysisforbioactivityofthe
ﬁnal product (Figure 1).
3 Engineering of lantipeptides has been
very fruitful and has been accomplished by manipulation of the
sequence of the precursor peptides in host strains and hetero-
logous expression systems
4 as well as with in vitro reconstituted
systems.
5 The former methods have the advantage of potential
scale-up, whereas the in vitro approach allows introduction of
nonproteinogenic amino acids. Any improved variants identiﬁed
bytheinvitromethodcouldinprinciplebeproducedinvivousing
amber stop-codon suppression technology.
6 Unfortunately, at
present this methodology is not available for most lantipeptide
expression hosts. To be able to take full advantage of in vivo
introduction of nonproteinogenic amino acids, production of
lantipeptides in Escherichia coli would be highly desirable, but
only a single such example has been reported to date for a
truncated analog of the class II lantibiotic nukacin ISK-1.
7 We
present here seven examples of production of mature full-length
lantipeptides from diﬀerent phylogenetic backgrounds in E. coli.
We ﬁrst focused our eﬀorts on the prochlorosins. These
lantipeptides were recently discovered as products of the ubiqui-
tous marine cyanobacterium Prochlorococcus.
8 The production
levels are less than 10 μg of prochlorosin from 20 L of culture of
Prochlorococcus MIT 9313, insuﬃcient to investigate their func-
tion. Prochlorosins are members of the class II lantipeptides that
are modiﬁed by a single bifunctional lanthionine synthetase that
carries out both dehydration and cyclization reactions,
8 but they
have unusually large leader peptides (Figure S1). We selected
prochlorosin 1.7, 2.11, 3.2, and 3.3 (Figure 2) for investigation
because their biosynthesis has been reconstituted in vitro.
8 The
genes for their precursor peptides and the synthetase ProcM
were cloned into the pRSFDUET-1 vector as a biscistronic
construct. For rapid puriﬁcation, an N-terminal hexahistidine
tag was encoded at the N-termini of the ProcA peptides, and
artiﬁcial protease cleavage sites were introduced between the
leader and core peptides to allow in vitro removal of the leader
sequence (Figure S1).
9 E. coli BL21 (DE3) cells were trans-
formed with the plasmids, and the cells were grown in Luria-
Bertani broth and induced with IPTG. After harvest and lysis of
the cells followed by immobilized metal aﬃnity chromatography
(IMAC) puriﬁcation of the ProcA peptides from the soluble
protein fraction, the fully modiﬁed peptides were isolated in
yields ranging from 10 to 35 mg per liter of culture, signiﬁcantly
more than the 1.5 mg/L of modiﬁed NukA reported previously
using a diﬀerent expression system.
7 This production level was
surprising because when lantipeptide precursor peptides are
expressed in the absence of ProcM, they are almost exclusively
present in inclusion bodies.
8,10 Hence, posttranslational modiﬁ-
cations improve the solubility of the products. The puriﬁed
peptides were then treated with the appropriate commercial
protease(trypsinforProcA1.7,Lys-CforProcA2.11and3.3,and
Figure 1. Posttranslational modiﬁcations in lantipeptide biosynthesis.
Dha,dehydrolalanine;Dhb,dehydrobutyrine;Abu,2-aminobutyricacid.
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TEV protease for ProcA3.2, Figure 3A-C) and puriﬁed by
HPLC. Although, in principle, the proteolytic step could be
carriedoutinvivobyintroductionofthegeneforthebifunctional
protease transporter, we elected to remove the leader peptide in
vitro to avoid complications often encountered in heterologous
expression of proteases and to avoid any potential cytotoxic
eﬀects of the ﬁnal posttranslationally modiﬁed products.
11 After
HPLC puriﬁcation, pure prochlorosins were obtained (Figures
S2 and S3). The puriﬁed, modiﬁed peptides were analyzed next
by tandem mass spectrometry (MS) displaying the same frag-
mentation patterns as observed previously
8 (Figure S4) demon-
strating that the ring topology of the products is the same as that
of the natural products.
12
As proof of concept of introducing non-natural amino acids
into lantipeptides in vivo, procA3.2 was mutated to introduce an
amber stop codon (TAG) at the position of Phe26. The gene
product was coexpressed with ProcM and with an orthogonal
tRNA/tRNA synthetase pair that incorporates the photo-cross-
linking amino acid p-benzoyl-L-Phe (pBpa) at the site of the
amber stop codon.
13 The resulting peptide containing the
nonproteinogenic amino acid pBpa was fully modiﬁed resulting
in prochlorosin 3.2 containing a photo-cross-linking amino acid
(Figure3D)thatwillprovideavaluabletoolfordeterminationof
its biological activity.
Wenextturnedtothetwo-componentlantibiotichaloduracin.
Haloduracin consists of two posttranslationally modiﬁed pep-
tides, HalR and Halβ (Figure 4), that display potent synergistic
antimicrobial activity that requires both peptides.
14 HalR and
Halβ are only produced by Bacillus halodurans on solid, rich
medium,
9 preventing isotopic labeling of the peptides for NMR
studiestoinvestigatetheirlikelyinteractionwithlipidII.
15Ifthey
couldbeproducedinliquidmediuminE.coli,itwouldopenupa
route to isotopically labeled peptides. Thus, the gene for HalA1
with a Factor Xa protease cleavage site between its leader and
Figure 2. (A) Sequences of the ProcA lantipeptide core peptides used
in this study. The residue replaced by pBpa in this work is highlighted in
red. For the sequences of the leader peptides, see Figure S1. (B)
Representative structures of prochlorosins 1.7 and 3.3. Abu, 2-amino-
butyric acid; Dha, dehydroalanine; Dhb, dehydrobutyrine.
Figure3. MALDI-MSspectraofprecursorpeptidesmodiﬁedbyProcM
in E. coli and treated with a protease to remove the leader peptide. (A)
ProcA1.7,(B)ProcA2.11,(C)ProcA3.3,and(D)ProcA3.2Phe26pBpa.
Figure 4. (A) Sequences of the HalA core peptides. For the sequences
oftheleaderpeptides,seeFigureS1.(B)StructuresofhaloduracinRand
β. Abu, 2-aminobutyric acid; Dha, dehydroalanine; Dhb, dehydrobutyr-
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core peptide was inserted into pRSFDUET-1 along with its
bifunctional modiﬁcation enzyme HalM1 that both dehydrates
and cyclizes the peptide.
12 E. coli BL21 (DE3) cells were
transformed, grown at 37 C, and induced as described above.
After harvest, lysis, IMAC puriﬁcation, and proteolysis with
Factor Xa to remove the leader peptide, the modiﬁed HalA1
peptide (termed HalR)
9 was obtained (Figure 5A). Similar
results were obtained for HalA2 (Figure 5B) showing that the
methodology extends to class II lantibiotics from bacilli with
prototypical leader peptides for this class.
16 The puriﬁed HalR
thus obtained was combinedwithHalβ forbioactivity assays and
demonstrated very similar antimicrobial activity against Lacto-
coccus lactis as an authentic sample of these peptides obtained
from the producing organism (Figure 6).
12 Repeating the
expression in minimal medium required for producing isotopi-
cally labeled product for NMR studies was also successful albeit
theyieldwasreduced(∼1mgofpureHalA1perliterofculture).
Lastly we turned to the class I lantibiotic nisin, which is
assembled by two dedicated proteins, NisB for dehydration and
NisCforcyclization (Figure1). To date, in vitro reconstitutionof
a puriﬁed LanB dehydratase has not been achieved, as LanB
proteins that were heterologously expressed in E. coli did not
display any in vitro activity.
17 Thus, production of nisin in
E. coli presented the most challenging system. The genes encod-
ing His6-NisA and NisB were inserted into the pRSFDUET-1
vector, and the nisC gene was inserted into a pACYCDUET-1
plasmid. E. coli BL21 (DE3) cells were transformed with both
plasmids,grownat37ConLBmedium,andinducedwithIPTG.
After harvesting the cells, lysis, and IMAC puriﬁcation, 24 mg of
fully modiﬁed NisA were obtained per liter of culture. The leader
peptide was then removed using trypsin,
18 and the ﬁnal product
wasanalyzedbybioassaysandtandemMS(Figures6,S6,andS7)
demonstrating the formation of authentic nisin. These experi-
ments demonstrate that active NisB can be expressed in E. coli
opening up the potential of future mechanistic studies.
In summary, we demonstrate that three very diﬀerent types of
lantipeptides can be produced in E. coli. This methodology may
be useful for cryptic lantipeptides that cannot be isolated from
theproducerstrain,forcompoundsthatareproducedinverylow
abundancies, or for preparing these compounds in isotopically
labeled forms. Furthermore, this methodology may open up
investigations of the LanB proteins and introduction of non-
proteinogenic amino acids into lantipeptides using stop-codon
suppression technology.
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